A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene ...
Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due to ...
Investigational BAY 2927088 is an oral, small molecule, tyrosine kinase inhibitor as a potential new targeted therapy for patients with non-small cell lung cancer (NSCLC) harboring HER2 activating ...
The FDA on Friday granted accelerated approval to zongertinib (Hernexeos) for non-squamous non-small cell lung cancer (NSCLC) patients harboring HER2 tyrosine kinase domain (TKD) activating mutations.
Many people are familiar with histamine, a biological molecule that serves as a key driver of allergic reactions and other ...
Using ribosome engineering (RE), researchers from Shinshu University introduced mutations affecting the protein synthesis ...
RYZ101 (225Ac-DOTATATE) in patients with estrogen receptor-positive, human epidermal growth factor receptor 2–negative, locally advanced and unresectable, or metastatic breast cancer progressing after ...
Many people are familiar with histamine, a biological molecule, that serves as a key driver of allergic reactions and other immune responses. However ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback